about
The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocolMultielectrode Pulmonary Vein Ablation Catheter (PVAC(®)): current data on results and risks.Data on procedural handling and complications of pulmonary vein isolation using the pulmonary vein ablation catheter GOLD®.Catheter ablation of atrial fibrillation and atrial flutter in patients with diabetes mellitus: Who benefits and who does not? Data from the German ablation registry.Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data.Body surface area of ST elevation and the presence of late potentials correlate to the inducibility of ventricular tachyarrhythmias in Brugada syndrome.The long QT syndrome: considerations in the athletic population.Electrical alternans in long QT syndrome resembling a Brugada syndrome pattern.Recurrent syncope triggered by inappropriate sinus tachycardia.Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome.Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up.[Long QT syndrome and Brugada syndrome. Drugs, ablation or ICD?].Electrocardiographic risk stratification in families with congenital long QT syndrome.Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.Prevalence of supraventricular tachyarrhythmias in a cohort of 115 patients with Brugada syndrome.Bradyarrhythmias and conduction blocks.Inherited long QT syndrome: clinical manifestation, genetic diagnostics, and therapy.[Early repolarisation. A dilemma of risk stratification].[Brugada syndrome. Current clinical aspects and risk stratification].Improved Clinical Risk Stratification in Patients with Long QT Syndrome? Novel Insights from Multi-Channel ECGs[Indications for implantable loop recorders in patients with channelopathies and ventricular tachycardias].Predisposing factors for atrial fibrillation in the elderly.Electrophysiological alterations in a murine model of chronic coxsackievirus B3 myocarditisA heterozygous deletion mutation in the cardiac sodium channel gene SCN5A with loss- and gain-of-function characteristics manifests as isolated conduction disease, without signs of Brugada or long QT syndrome.Molecular mechanisms of inherited ventricular arrhythmias.Antiarrhythmic therapy in heart failure.Triple threat: the Na+/Ca2+ exchanger in the pathophysiology of cardiac arrhythmia, ischemia and heart failure.Recent advances in the entirely subcutaneous ICD System.Primary prevention of sudden cardiac death.By Regulating Mitochondrial Ca2+-Uptake UCP2 Modulates Intracellular Ca2+.Influence of Clinical Parameters and Anticoagulation on Intraprocedural Cerebral Microembolic Signals during Pulmonary Vein IsolationArrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD?Gender differences in cardiac arrhythmias.Is there a role for amiodarone in the era of the implantable cardioverter-defibrillator?Intraoperative Defibrillation Testing of Subcutaneous Implantable Cardioverter-Defibrillator Systems-A Simple Issue?Pulmonary vein isolation in patients with paroxysmal atrial fibrillation is associated with regional cardiac sympathetic denervation.Catheter ablation of ventricular tachycardia. From indication to three-dimensional mapping technology.Spontaneous Brugada electrocardiogram patterns are rare in the German general population: results from the KORA study.Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.Prophylactic proton pump inhibition after atrial fibrillation ablation: is there any evidence?
P50
Q28178857-C8523C98-7515-4959-A575-3551620E0B15Q30839235-010BC2B4-5F6D-4352-828F-786E930BB79BQ31034047-52C55B2B-AAEE-4698-9575-7F505829F267Q31071874-A55DA7DD-C8DE-49EE-B5A3-0B2911032ED2Q31111759-EAD67C4D-2723-49C8-B686-DBE18C1741E3Q33148073-F5A390F0-094D-4022-B1E1-B63835E6EF24Q33149076-2412B129-646B-4C96-9881-E9056424E336Q33150569-D942CB23-E5A4-4AD5-8242-2B30380F436FQ33151872-99BE9419-066B-425B-81B8-94BCA171BA92Q33152228-967C6EBC-C045-4B18-BFD8-AA221B0D92B3Q33152558-D046AEAD-DAD5-4A99-9BA5-55A837110ECFQ33152640-9E63F501-4528-431E-923E-570D86818F86Q33154118-108F8254-3821-4072-BA40-CE4D8B9B5518Q33155155-7BFE9B80-4D93-4CC3-AAEE-E5461AEBA025Q33156554-CCC8E0E2-FB74-45C6-8F50-1557CD85825CQ33161334-B1FDB6B1-8004-4829-A77A-15E030908077Q33161775-EBAE3A04-B867-4234-8CDA-528A60C73CB2Q33162940-F51980AF-98BD-49E4-96D2-317CF51C78C0Q33163843-CB681F37-D19D-4DEB-A63B-FA2305E151C7Q33167382-AD1A1AED-A7F7-465B-91CB-B7E982A44921Q33167900-CDD29A6D-CF8C-4D2C-8000-A36CD3892F2CQ33766891-0D6718C0-7160-4BB5-809A-546BC1955BC5Q33828989-74BE5DB4-80B7-46B1-94F0-224997D5EA05Q34808264-7581C44C-AE6A-464A-A011-1E055DB2DBD8Q35062821-6A984321-F1F1-4CE6-9246-029DA82AF40EQ35084645-ACB7559E-0E2E-4415-8B01-9003BD60779EQ35523734-0A0DCABA-3089-4C64-ACB0-3C28226AD39AQ35659336-B8DFEFB5-D6C9-4424-83A8-5C171DB0B9A0Q35772865-EFAE4B86-9FD5-4FE1-9A6F-D89768DD9BD2Q35915724-1CB0E7C0-06DB-4598-91F2-5696BBDAD113Q36057957-E8A1174B-62D3-4EEB-92BC-1872D0CAF296Q36116944-CDE49A03-97C2-4F06-BC7D-E5CCABEEAB7EQ36244991-05EAD9C1-5E5C-4C1E-A77B-3BDD7760E937Q36433243-EE33C75E-AD95-4773-B2ED-7B20C222D9C2Q37090875-378E8704-5F8F-4A50-B209-FF1958CC3974Q37480024-D4518CD0-B812-4DF7-B795-AD3BE2E6F4D2Q37483529-309908C2-93BD-4531-A028-F46CE974CAB8Q37572102-A89EBD4E-2166-470D-BE23-0728CB3507C2Q37835555-4D81408E-CFB2-4694-AE91-3D72ADA42A60Q37874378-6405364C-6736-4CDD-8003-308FA7C38CF9
P50
name
Lars Eckardt
@en
type
label
Lars Eckardt
@en
prefLabel
Lars Eckardt
@en